[State of GABA-benzodiazepine receptor complex in diabetic neuropathy: effect of nicotinamide and nicotinoyl-GABA].
An increase in GABA uptake by isolated rat brain synaptic endings as well as a decrease of pharmacologically active GABA analogue muscimol specific binding have indicated a physiologically drastic failure in realization of GABA-mediated inhibitory effects in CNS induced by diabetic encephalopathy. In spite of the impairment of inhibitory function of GABAergic transmission in diabetes a crucial activation of benzodiazepine receptors was determined, as it is tested by the increase in specific binding of flunitrazepam by synaptic membranes. This increase may play an important role in endogenous control of neural activity associated with the factors undefined so far. Using the approach that GABA, and several synthetic GABA agonists, appear to increase the affinity of the benzodiazepine recognition sites for such ligands, presumably by some allosteric mechanism, the findings concerning the in vitro binding assay technique confirm at least some of the functional characteristics observed between GABA and benzodiazepine receptors in vivo under pathological conditions. Indeed, the absence of activating effect on the affinity of flunitrazepam specific binding in the presence of micromolar concentrations of exogenous GABA implicate diabetes-induced alterations in coupling GABA- and benzodiazepine receptors that might be linked to changes in conformantial state of this membrane-bound complex and could partially explain diabetes-induced impairments of GABAergic transmission evaluated in the present study. Our study suggests that nicotinamide and especially GABA play an important role in improving the functioning of brain GABA-benzodiazepine complex impaired in diabetes through specific ligand-mediated mechanism and can be useful in the management of diabetes-associated brain failures.
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv. kuch@biochem.kiev.ua
T M
TM
Kuchmerovs'ka
I O
IO
Shymans'kyĭ
H V
HV
Donchenko
S P
SP
Stepanenko
D000818:Animals; D001921:Brain / Q000378:metabolism; D003929:Diabetic Neuropathies / Q000378:metabolism*; D005445:Flunitrazepam / Q000378:metabolism; D018755:GABA Agonists / Q000378:metabolism; D018757:GABA Modulators / Q000378:metabolism; D008024:Ligands; D008297:Male; D009118:Muscimol / Q000378:metabolism; D009536:Niacinamide / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D018079:Receptors, GABA / Q000378:metabolism*; D013570:Synaptic Membranes / Q000187:drug effects / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000502:physiology*
D018755:GABA Agonists; D018757:GABA Modulators; D008024:Ligands; D018079:Receptors, GABA; D009536:Niacinamide; D009118:Muscimol; C044905:nicotinoyl-GABA; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam